English

TETRAPHASE PHARMACEUTICALS INC

EDGAR

TTPH Quarterly report (10-Q) · filed 2020-05-07

35 filing records in this dataset, filed from 2013-02-11 to 2020-05-07. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1.76 million USD

2020 Q1 · USD

Exact inputs and evidence

Revenue: 1755000 USD Source

Operating margin

-698.8%

2020 Q1 · %

Exact inputs and evidence

Operating Income: -12264000 USD Source
Revenue: 1755000 USD Source

Operating cash flow

-11.2 million USD

2020 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -11155000 USD Source

Cash and cash equivalents: 26.1 million USD 2020-03-31 Source
Exact value

26146000 USD
Long-term debt including current maturities: 28.7 million USD 2019-06-30 Source
Exact value

28748000 USD
Shares outstanding: 7.26 million shares 2020-03-31 Source
Exact value

7259000 shares

Reported share-count change

-86.49% · -46.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

53746000 shares · 2019-03-31· Source
7259000 shares · 2020-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

7.86 million USD

2019-04-01 – 2020-03-31

Exact inputs and evidence

Revenue: 1073000 USD · 2019-04-01 – 2019-06-30 Source
Revenue: 3340000 USD · 2019-07-01 – 2019-09-30 Source
Revenue: 1690000 USD · 2019-10-01 – 2019-12-31 Source
Revenue: 1755000 USD · 2020-01-01 – 2020-03-31 Source

Net income

-62.7 million USD

2019-04-01 – 2020-03-31

Exact inputs and evidence

Net income: -22921000 USD · 2019-04-01 – 2019-06-30 Source
Net income: -16304000 USD · 2019-07-01 – 2019-09-30 Source
Net income: -11372000 USD · 2019-10-01 – 2019-12-31 Source
Net income: -12124000 USD · 2020-01-01 – 2020-03-31 Source

Operating cash flow

-54.7 million USD

2019-04-01 – 2020-03-31

Exact inputs and evidence

Operating cash flow: -36755000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -20119000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -52731000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -36755000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -63670000 USD · 2019-01-01 – 2019-12-31 Source
Operating cash flow: -52731000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -11155000 USD · 2020-01-01 – 2020-03-31 Source

Capital expenditure

108 thousand USD

2019-01-01 – 2019-12-31

Exact inputs and evidence

Capital expenditure: 98000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 106000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 98000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 108000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 106000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 108000 USD · 2019-01-01 – 2019-12-31 Source
Capital expenditure: 108000 USD · 2019-01-01 – 2019-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2020-05-07.

Financial data available through: 2019-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2019-12-31
Operating income: 9 of 11 periods available· newest 2019-12-31
Net income: 11 of 11 periods available· newest 2019-12-31
Operating cash flow: 9 of 11 periods available· newest 2019-12-31
Capital expenditure: 9 of 11 periods available· newest 2019-12-31
Total assets: 9 of 11 periods available· newest 2019-12-31
Total liabilities: 1 of 11 periods available· newest 2018-12-31
Current assets: 9 of 11 periods available· newest 2019-12-31
Current liabilities: 9 of 11 periods available· newest 2019-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2019-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2018-12-31
Shares outstanding: 9 of 11 periods available· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-61%

Prior period

USD 18.9 million

2018-01-01 – 2018-12-31
Current period

USD 7.38 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

7376000 − 18904000 = -11528000 USD

18904000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
7376000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · TETRAPHASE PHARMACEUTICALS INC · 2019-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Year-over-year change in Revenue: -11528000 USD Concept: fundies:Revenue Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 7376000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#173546 Filing: 000156459020010220 Input fundies:Revenue: 18904000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#173774 Filing: 000156459020010220
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 2.07 million

Prior period

−USD 72.16 million

2018-01-01 – 2018-12-31
Current period

−USD 70.09 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-70085000 − -72158000 = 2073000 USD

-72158000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-70085000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TETRAPHASE PHARMACEUTICALS INC · 2019-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Year-over-year change in Net income: 2073000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -70085000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#177378 Filing: 000156459020010220 Input fundies:NetIncome: -72158000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#177532 Filing: 000156459020010220
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 4.04 million

Prior period

−USD 59.63 million

2018-01-01 – 2018-12-31
Current period

−USD 63.67 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-63670000 − -59628000 = -4042000 USD

-59628000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-63670000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TETRAPHASE PHARMACEUTICALS INC · 2019-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Year-over-year change in Operating cash flow: -4042000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -63670000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#193878 Filing: 000156459020010220 Input fundies:OperatingCashFlow: -59628000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#194090 Filing: 000156459020010220
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-47.1%

Prior period

USD 204,000

2018-01-01 – 2018-12-31
Current period

USD 108,000

2019-01-01 – 2019-12-31

Exact inputs and evidence

108000 − 204000 = -96000 USD

204000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
108000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · TETRAPHASE PHARMACEUTICALS INC · 2019-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Year-over-year change in Capital expenditure: -96000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 108000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#194705 Filing: 000156459020010220 Input fundies:CapitalExpenditure: 204000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#194914 Filing: 000156459020010220
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 7.38 million 100% of revenue
Operating costs Derived USD 74.91 million 1,016% of revenue
Operating income −USD 67.53 million −916% of revenue
Tax, interest and other Derived USD 2.55 million 35% of revenue
Net income −USD 70.09 million −950% of revenue

Cash

Operating cash flow −USD 63.67 million −863% of revenue
Capital expenditure USD 108,000 1.5% of revenue
Free cash flow Derived −USD 63.78 million −865% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2011 Operating loss: operating costs were 11,682% of revenue.
2012 Operating loss: operating costs were 284% of revenue.
2013 Operating loss: operating costs were 369% of revenue.
2014 Operating loss: operating costs were 823% of revenue.
2015 Operating loss: operating costs were 810% of revenue.
2016 Operating loss: operating costs were 1,613% of revenue.
2017 Operating loss: operating costs were 1,297% of revenue.
2018 Operating loss: operating costs were 488% of revenue.
2019 Operating loss: operating costs were 1,016% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2011 2011-01-01 – 2011-12-31	185000	21611000 Derived	-21426000	138000 Derived	-21564000	-19941000 Derived	Source 2011-01-01 – 2011-12-31: 185000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -21426000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -21564000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -19876000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 65000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	7600000	21603000 Derived	-14003000	1084000 Derived	-15087000	-16711000 Derived	Source 2012-01-01 – 2012-12-31: 7600000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -14003000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -15087000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -16657000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 54000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	10486000	38676000 Derived	-28190000	1446000 Derived	-29636000	-24635000 Derived	Source 2013-01-01 – 2013-12-31: 10486000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -28190000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -29636000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -24506000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 129000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	9098000	74864000 Derived	-65766000	976000 Derived	-66742000	-57814000 Derived	Source 2014-01-01 – 2014-12-31: 9098000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -65766000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -66742000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -57623000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 191000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	11686000	94684000 Derived	-82998000	191000 Derived	-83189000	-77545000 Derived	Source 2015-01-01 – 2015-12-31: 11686000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -82998000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -83189000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -76707000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 838000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	5145000	82975000 Derived	-77830000	-350000 Derived	-77480000	-64159000 Derived	Source 2016-01-01 – 2016-12-31: 5145000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -77830000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -77480000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -63766000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 393000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	9666000	125381000 Derived	-115715000	-963000 Derived	-114752000	-98821000 Derived	Source 2017-01-01 – 2017-12-31: 9666000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -115715000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -114752000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -98050000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 771000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	18904000	92185000 Derived	-73281000	-1123000 Derived	-72158000	-59832000 Derived	Source 2018-01-01 – 2018-12-31: 18904000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -73281000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -72158000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -59628000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 204000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	7376000	74908000 Derived	-67532000	2553000 Derived	-70085000	-63778000 Derived	Source 2019-01-01 – 2019-12-31: 7376000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -67532000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -70085000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -63670000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 108000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 7.4M 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Revenue	185000	Revenue: 185000 Open source
20122012-12-31	Revenue	7600000	Revenue: 7600000 Open source
20132013-12-31	Revenue	10486000	Revenue: 10486000 Open source
20142014-12-31	Revenue	9098000	Revenue: 9098000 Open source
20152015-12-31	Revenue	11686000	Revenue: 11686000 Open source
20162016-12-31	Revenue	5145000	Revenue: 5145000 Open source
20172017-12-31	Revenue	9666000	Revenue: 9666000 Open source
20182018-12-31	Revenue	18904000	Revenue: 18904000 Open source
20192019-12-31	Revenue	7376000	Revenue: 7376000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-61% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Year over year	No prior comparable period	Revenue: 185000 Open source
20122012-12-31	Year over year	4,008.1%	Revenue: 7600000 Open source Revenue: 185000 Open source
20132013-12-31	Year over year	38%	Revenue: 10486000 Open source Revenue: 7600000 Open source
20142014-12-31	Year over year	-13.2%	Revenue: 9098000 Open source Revenue: 10486000 Open source
20152015-12-31	Year over year	28.4%	Revenue: 11686000 Open source Revenue: 9098000 Open source
20162016-12-31	Year over year	-56%	Revenue: 5145000 Open source Revenue: 11686000 Open source
20172017-12-31	Year over year	87.9%	Revenue: 9666000 Open source Revenue: 5145000 Open source
20182018-12-31	Year over year	95.6%	Revenue: 18904000 Open source Revenue: 9666000 Open source
20192019-12-31	Year over year	-61%	Revenue: 7376000 Open source Revenue: 18904000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -915.6% 2019

Net margin -950.2% 2019

Free cash flow margin -864.7% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Operating margin	-11,581.6%	Operating Income: -21426000 Open source Revenue: 185000 Open source
20122012-12-31	Operating margin	-184.3%	Operating Income: -14003000 Open source Revenue: 7600000 Open source
20132013-12-31	Operating margin	-268.8%	Operating Income: -28190000 Open source Revenue: 10486000 Open source
20142014-12-31	Operating margin	-722.9%	Operating Income: -65766000 Open source Revenue: 9098000 Open source
20152015-12-31	Operating margin	-710.2%	Operating Income: -82998000 Open source Revenue: 11686000 Open source
20162016-12-31	Operating margin	-1,512.7%	Operating Income: -77830000 Open source Revenue: 5145000 Open source
20172017-12-31	Operating margin	-1,197.1%	Operating Income: -115715000 Open source Revenue: 9666000 Open source
20182018-12-31	Operating margin	-387.6%	Operating Income: -73281000 Open source Revenue: 18904000 Open source
20192019-12-31	Operating margin	-915.6%	Operating Income: -67532000 Open source Revenue: 7376000 Open source
20112011-12-31	Net margin	-11,656.2%	Net Income: -21564000 Open source Revenue: 185000 Open source
20122012-12-31	Net margin	-198.5%	Net Income: -15087000 Open source Revenue: 7600000 Open source
20132013-12-31	Net margin	-282.6%	Net Income: -29636000 Open source Revenue: 10486000 Open source
20142014-12-31	Net margin	-733.6%	Net Income: -66742000 Open source Revenue: 9098000 Open source
20152015-12-31	Net margin	-711.9%	Net Income: -83189000 Open source Revenue: 11686000 Open source
20162016-12-31	Net margin	-1,505.9%	Net Income: -77480000 Open source Revenue: 5145000 Open source
20172017-12-31	Net margin	-1,187.2%	Net Income: -114752000 Open source Revenue: 9666000 Open source
20182018-12-31	Net margin	-381.7%	Net Income: -72158000 Open source Revenue: 18904000 Open source
20192019-12-31	Net margin	-950.2%	Net Income: -70085000 Open source Revenue: 7376000 Open source
20112011-12-31	Free cash flow margin	-10,778.9%	Revenue: 185000 Open source Operating Cash Flow: -19876000 Open source Capital Expenditure: 65000 Open source
20122012-12-31	Free cash flow margin	-219.9%	Revenue: 7600000 Open source Operating Cash Flow: -16657000 Open source Capital Expenditure: 54000 Open source
20132013-12-31	Free cash flow margin	-234.9%	Revenue: 10486000 Open source Operating Cash Flow: -24506000 Open source Capital Expenditure: 129000 Open source
20142014-12-31	Free cash flow margin	-635.5%	Revenue: 9098000 Open source Operating Cash Flow: -57623000 Open source Capital Expenditure: 191000 Open source
20152015-12-31	Free cash flow margin	-663.6%	Revenue: 11686000 Open source Operating Cash Flow: -76707000 Open source Capital Expenditure: 838000 Open source
20162016-12-31	Free cash flow margin	-1,247%	Revenue: 5145000 Open source Operating Cash Flow: -63766000 Open source Capital Expenditure: 393000 Open source
20172017-12-31	Free cash flow margin	-1,022.4%	Revenue: 9666000 Open source Operating Cash Flow: -98050000 Open source Capital Expenditure: 771000 Open source
20182018-12-31	Free cash flow margin	-316.5%	Revenue: 18904000 Open source Operating Cash Flow: -59628000 Open source Capital Expenditure: 204000 Open source
20192019-12-31	Free cash flow margin	-864.7%	Revenue: 7376000 Open source Operating Cash Flow: -63670000 Open source Capital Expenditure: 108000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -63.7M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Operating cash flow	-19876000	Operating Cash Flow: -19876000 Open source
20122012-12-31	Operating cash flow	-16657000	Operating Cash Flow: -16657000 Open source
20132013-12-31	Operating cash flow	-24506000	Operating Cash Flow: -24506000 Open source
20142014-12-31	Operating cash flow	-57623000	Operating Cash Flow: -57623000 Open source
20152015-12-31	Operating cash flow	-76707000	Operating Cash Flow: -76707000 Open source
20162016-12-31	Operating cash flow	-63766000	Operating Cash Flow: -63766000 Open source
20172017-12-31	Operating cash flow	-98050000	Operating Cash Flow: -98050000 Open source
20182018-12-31	Operating cash flow	-59628000	Operating Cash Flow: -59628000 Open source
20192019-12-31	Operating cash flow	-63670000	Operating Cash Flow: -63670000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -63.8M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Free cash flow	-19941000	Operating Cash Flow: -19876000 Open source Capital Expenditure: 65000 Open source
20122012-12-31	Free cash flow	-16711000	Operating Cash Flow: -16657000 Open source Capital Expenditure: 54000 Open source
20132013-12-31	Free cash flow	-24635000	Operating Cash Flow: -24506000 Open source Capital Expenditure: 129000 Open source
20142014-12-31	Free cash flow	-57814000	Operating Cash Flow: -57623000 Open source Capital Expenditure: 191000 Open source
20152015-12-31	Free cash flow	-77545000	Operating Cash Flow: -76707000 Open source Capital Expenditure: 838000 Open source
20162016-12-31	Free cash flow	-64159000	Operating Cash Flow: -63766000 Open source Capital Expenditure: 393000 Open source
20172017-12-31	Free cash flow	-98821000	Operating Cash Flow: -98050000 Open source Capital Expenditure: 771000 Open source
20182018-12-31	Free cash flow	-59832000	Operating Cash Flow: -59628000 Open source Capital Expenditure: 204000 Open source
20192019-12-31	Free cash flow	-63778000	Operating Cash Flow: -63670000 Open source Capital Expenditure: 108000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

35.2% 2018

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2011-12-31	Liabilities / assets	Not reported	Total Assets: 24069000 Open source
2012-12-31	Liabilities / assets	Not reported	Total Assets: 14072000 Open source
2013-12-31	Liabilities / assets	Not reported	Total Assets: 105886000 Open source
2014-12-31	Liabilities / assets	Not reported	Total Assets: 127204000 Open source
2015-12-31	Liabilities / assets	Not reported	Total Assets: 214917000 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 151710000 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 149040000 Open source
20182018-12-31	Liabilities / assets	35.2%	Total Liabilities: 43262000 Open source Total Assets: 122944000 Open source
2019-12-31	Liabilities / assets	Not reported	Total Assets: 36385000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.71× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Current assets / current liabilities	3.35×	Current Assets: 23374000 Open source Current Liabilities: 6974000 Open source
20122012-12-31	Current assets / current liabilities	1.43×	Current Assets: 12381000 Open source Current Liabilities: 8661000 Open source
20132013-12-31	Current assets / current liabilities	7.99×	Current Assets: 105420000 Open source Current Liabilities: 13191000 Open source
20142014-12-31	Current assets / current liabilities	7.33×	Current Assets: 126597000 Open source Current Liabilities: 17276000 Open source
20152015-12-31	Current assets / current liabilities	19.98×	Current Assets: 213768000 Open source Current Liabilities: 10697000 Open source
20162016-12-31	Current assets / current liabilities	13.09×	Current Assets: 150457000 Open source Current Liabilities: 11495000 Open source
20172017-12-31	Current assets / current liabilities	7.96×	Current Assets: 147446000 Open source Current Liabilities: 18525000 Open source
20182018-12-31	Current assets / current liabilities	7.78×	Current Assets: 116472000 Open source Current Liabilities: 14971000 Open source
20192019-12-31	Current assets / current liabilities	2.71×	Current Assets: 26493000 Open source Current Liabilities: 9770000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2010 2010-01-01 – 2010-12-31	−USD 17.48 million Exact value Exact value: -17478000 USD 2010-01-01 – 2010-12-31: -17478000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2010-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -17478000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17478000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312514086844/ttph-20131231.xml#129019 Filing: 000119312514086844 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period.
2011 2011-01-01 – 2011-12-31	−USD 21.56 million Exact value Exact value: -21564000 USD 2011-01-01 – 2011-12-31: -21564000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2011-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -21564000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21564000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312514086844/ttph-20131231.xml#140776 Filing: 000119312514086844 The citation records this snapshot. The page link may show a newer release later.	−USD 19.88 million Exact value Exact value: -19876000 USD 2011-01-01 – 2011-12-31: -19876000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TETRAPHASE PHARMACEUTICALS INC · 2011-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Operating Cash Flow: -19876000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19876000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312514086844/ttph-20131231.xml#135545 Filing: 000119312514086844 The citation records this snapshot. The page link may show a newer release later.	USD 65,000 Exact value Exact value: 65000 USD 2011-01-01 – 2011-12-31: 65000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TETRAPHASE PHARMACEUTICALS INC · 2011-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Capital Expenditure: 65000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 65000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312514086844/ttph-20131231.xml#141576 Filing: 000119312514086844 The citation records this snapshot. The page link may show a newer release later.	−USD 19.94 million Calculation and evidence -19876000 − 65000 USD Exact free cash flow: -19941000 USD 2011-01-01 – 2011-12-31: -19876000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 65000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TETRAPHASE PHARMACEUTICALS INC · 2011-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Free cash flow: -19941000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19876000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312514086844/ttph-20131231.xml#135545 Filing: 000119312514086844 Input fundies:CapitalExpenditure: 65000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312514086844/ttph-20131231.xml#141576 Filing: 000119312514086844 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	−USD 15.09 million Exact value Exact value: -15087000 USD 2012-01-01 – 2012-12-31: -15087000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2012-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -15087000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15087000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312515081060/ttph-20141231.xml#545070 Filing: 000119312515081060 The citation records this snapshot. The page link may show a newer release later.	−USD 16.66 million Exact value Exact value: -16657000 USD 2012-01-01 – 2012-12-31: -16657000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TETRAPHASE PHARMACEUTICALS INC · 2012-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Operating Cash Flow: -16657000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16657000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312515081060/ttph-20141231.xml#538479 Filing: 000119312515081060 The citation records this snapshot. The page link may show a newer release later.	USD 54,000 Exact value Exact value: 54000 USD 2012-01-01 – 2012-12-31: 54000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TETRAPHASE PHARMACEUTICALS INC · 2012-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Capital Expenditure: 54000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 54000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312515081060/ttph-20141231.xml#544806 Filing: 000119312515081060 The citation records this snapshot. The page link may show a newer release later.	−USD 16.71 million Calculation and evidence -16657000 − 54000 USD Exact free cash flow: -16711000 USD 2012-01-01 – 2012-12-31: -16657000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 54000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TETRAPHASE PHARMACEUTICALS INC · 2012-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Free cash flow: -16711000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16657000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312515081060/ttph-20141231.xml#538479 Filing: 000119312515081060 Input fundies:CapitalExpenditure: 54000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000119312515081060/ttph-20141231.xml#544806 Filing: 000119312515081060 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 29.64 million Exact value Exact value: -29636000 USD 2013-01-01 – 2013-12-31: -29636000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2013-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -29636000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29636000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459016013419/ttph-20151231.xml#150668 Filing: 000156459016013419 The citation records this snapshot. The page link may show a newer release later.	−USD 24.51 million Exact value Exact value: -24506000 USD 2013-01-01 – 2013-12-31: -24506000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TETRAPHASE PHARMACEUTICALS INC · 2013-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Operating Cash Flow: -24506000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24506000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459016013419/ttph-20151231.xml#181824 Filing: 000156459016013419 The citation records this snapshot. The page link may show a newer release later.	USD 129,000 Exact value Exact value: 129000 USD 2013-01-01 – 2013-12-31: 129000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TETRAPHASE PHARMACEUTICALS INC · 2013-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Capital Expenditure: 129000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 129000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459016013419/ttph-20151231.xml#182494 Filing: 000156459016013419 The citation records this snapshot. The page link may show a newer release later.	−USD 24.64 million Calculation and evidence -24506000 − 129000 USD Exact free cash flow: -24635000 USD 2013-01-01 – 2013-12-31: -24506000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 129000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TETRAPHASE PHARMACEUTICALS INC · 2013-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Free cash flow: -24635000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24506000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459016013419/ttph-20151231.xml#181824 Filing: 000156459016013419 Input fundies:CapitalExpenditure: 129000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459016013419/ttph-20151231.xml#182494 Filing: 000156459016013419 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 66.74 million Exact value Exact value: -66742000 USD 2014-01-01 – 2014-12-31: -66742000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2014-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -66742000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66742000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459017004141/ttph-20161231.xml#107487 Filing: 000156459017004141 The citation records this snapshot. The page link may show a newer release later.	−USD 57.62 million Exact value Exact value: -57623000 USD 2014-01-01 – 2014-12-31: -57623000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TETRAPHASE PHARMACEUTICALS INC · 2014-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Operating Cash Flow: -57623000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -57623000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459017004141/ttph-20161231.xml#130237 Filing: 000156459017004141 The citation records this snapshot. The page link may show a newer release later.	USD 191,000 Exact value Exact value: 191000 USD 2014-01-01 – 2014-12-31: 191000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TETRAPHASE PHARMACEUTICALS INC · 2014-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Capital Expenditure: 191000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 191000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459017004141/ttph-20161231.xml#130907 Filing: 000156459017004141 The citation records this snapshot. The page link may show a newer release later.	−USD 57.81 million Calculation and evidence -57623000 − 191000 USD Exact free cash flow: -57814000 USD 2014-01-01 – 2014-12-31: -57623000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 191000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TETRAPHASE PHARMACEUTICALS INC · 2014-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Free cash flow: -57814000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -57623000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459017004141/ttph-20161231.xml#130237 Filing: 000156459017004141 Input fundies:CapitalExpenditure: 191000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459017004141/ttph-20161231.xml#130907 Filing: 000156459017004141 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 83.19 million Exact value Exact value: -83189000 USD 2015-01-01 – 2015-12-31: -83189000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2015-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -83189000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83189000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#117253 Filing: 000156459018004528 The citation records this snapshot. The page link may show a newer release later.	−USD 76.71 million Exact value Exact value: -76707000 USD 2015-01-01 – 2015-12-31: -76707000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TETRAPHASE PHARMACEUTICALS INC · 2015-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Operating Cash Flow: -76707000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76707000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#140243 Filing: 000156459018004528 The citation records this snapshot. The page link may show a newer release later.	USD 838,000 Exact value Exact value: 838000 USD 2015-01-01 – 2015-12-31: 838000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TETRAPHASE PHARMACEUTICALS INC · 2015-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Capital Expenditure: 838000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 838000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#140913 Filing: 000156459018004528 The citation records this snapshot. The page link may show a newer release later.	−USD 77.55 million Calculation and evidence -76707000 − 838000 USD Exact free cash flow: -77545000 USD 2015-01-01 – 2015-12-31: -76707000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 838000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TETRAPHASE PHARMACEUTICALS INC · 2015-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Free cash flow: -77545000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76707000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#140243 Filing: 000156459018004528 Input fundies:CapitalExpenditure: 838000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#140913 Filing: 000156459018004528 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 77.48 million Exact value Exact value: -77480000 USD 2016-01-01 – 2016-12-31: -77480000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2016-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -77480000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -77480000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#117099 Filing: 000156459018004528 The citation records this snapshot. The page link may show a newer release later.	−USD 63.77 million Exact value Exact value: -63766000 USD 2016-01-01 – 2016-12-31: -63766000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TETRAPHASE PHARMACEUTICALS INC · 2016-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Operating Cash Flow: -63766000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -63766000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#139991 Filing: 000156459018004528 The citation records this snapshot. The page link may show a newer release later.	USD 393,000 Exact value Exact value: 393000 USD 2016-01-01 – 2016-12-31: 393000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TETRAPHASE PHARMACEUTICALS INC · 2016-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Capital Expenditure: 393000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 393000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#140704 Filing: 000156459018004528 The citation records this snapshot. The page link may show a newer release later.	−USD 64.16 million Calculation and evidence -63766000 − 393000 USD Exact free cash flow: -64159000 USD 2016-01-01 – 2016-12-31: -63766000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 393000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TETRAPHASE PHARMACEUTICALS INC · 2016-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Free cash flow: -64159000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -63766000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#139991 Filing: 000156459018004528 Input fundies:CapitalExpenditure: 393000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/ttph-20171231.xml#140704 Filing: 000156459018004528 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 114.75 million Exact value Exact value: -114752000 USD 2017-01-01 – 2017-12-31: -114752000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2017-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -114752000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -114752000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459019008034/ttph-20181231.xml#139035 Filing: 000156459019008034 The citation records this snapshot. The page link may show a newer release later.	−USD 98.05 million Exact value Exact value: -98050000 USD 2017-01-01 – 2017-12-31: -98050000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TETRAPHASE PHARMACEUTICALS INC · 2017-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Operating Cash Flow: -98050000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -98050000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459019008034/ttph-20181231.xml#156462 Filing: 000156459019008034 The citation records this snapshot. The page link may show a newer release later.	USD 771,000 Exact value Exact value: 771000 USD 2017-01-01 – 2017-12-31: 771000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TETRAPHASE PHARMACEUTICALS INC · 2017-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Capital Expenditure: 771000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 771000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459019008034/ttph-20181231.xml#157075 Filing: 000156459019008034 The citation records this snapshot. The page link may show a newer release later.	−USD 98.82 million Calculation and evidence -98050000 − 771000 USD Exact free cash flow: -98821000 USD 2017-01-01 – 2017-12-31: -98050000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 771000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TETRAPHASE PHARMACEUTICALS INC · 2017-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Free cash flow: -98821000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -98050000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459019008034/ttph-20181231.xml#156462 Filing: 000156459019008034 Input fundies:CapitalExpenditure: 771000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459019008034/ttph-20181231.xml#157075 Filing: 000156459019008034 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 72.16 million Exact value Exact value: -72158000 USD 2018-01-01 – 2018-12-31: -72158000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2018-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -72158000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -72158000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#177532 Filing: 000156459020010220 The citation records this snapshot. The page link may show a newer release later.	−USD 59.63 million Exact value Exact value: -59628000 USD 2018-01-01 – 2018-12-31: -59628000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TETRAPHASE PHARMACEUTICALS INC · 2018-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Operating Cash Flow: -59628000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -59628000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#194090 Filing: 000156459020010220 The citation records this snapshot. The page link may show a newer release later.	USD 204,000 Exact value Exact value: 204000 USD 2018-01-01 – 2018-12-31: 204000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TETRAPHASE PHARMACEUTICALS INC · 2018-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Capital Expenditure: 204000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 204000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#194914 Filing: 000156459020010220 The citation records this snapshot. The page link may show a newer release later.	−USD 59.83 million Calculation and evidence -59628000 − 204000 USD Exact free cash flow: -59832000 USD 2018-01-01 – 2018-12-31: -59628000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 204000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TETRAPHASE PHARMACEUTICALS INC · 2018-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Free cash flow: -59832000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -59628000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#194090 Filing: 000156459020010220 Input fundies:CapitalExpenditure: 204000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#194914 Filing: 000156459020010220 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 70.09 million Exact value Exact value: -70085000 USD 2019-01-01 – 2019-12-31: -70085000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TETRAPHASE PHARMACEUTICALS INC · 2019-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Net Income: -70085000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -70085000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#177378 Filing: 000156459020010220 The citation records this snapshot. The page link may show a newer release later.	−USD 63.67 million Exact value Exact value: -63670000 USD 2019-01-01 – 2019-12-31: -63670000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TETRAPHASE PHARMACEUTICALS INC · 2019-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Operating Cash Flow: -63670000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -63670000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#193878 Filing: 000156459020010220 The citation records this snapshot. The page link may show a newer release later.	USD 108,000 Exact value Exact value: 108000 USD 2019-01-01 – 2019-12-31: 108000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TETRAPHASE PHARMACEUTICALS INC · 2019-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Capital Expenditure: 108000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 108000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#194705 Filing: 000156459020010220 The citation records this snapshot. The page link may show a newer release later.	−USD 63.78 million Calculation and evidence -63670000 − 108000 USD Exact free cash flow: -63778000 USD 2019-01-01 – 2019-12-31: -63670000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 108000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TETRAPHASE PHARMACEUTICALS INC · 2019-12-31 TETRAPHASE PHARMACEUTICALS INC (edgar:1373707) Free cash flow: -63778000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1373707?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -63670000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#193878 Filing: 000156459020010220 Input fundies:CapitalExpenditure: 108000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/ttph-20191231.xml#194705 Filing: 000156459020010220 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

35 filings · 2,116 latest values · 2,116 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001373707, 1373707, TTPH, edgar:1373707

Also known as TETRAPHASE PHARMACEUTICALS INC, Tetraphase Pharmaceuticals Inc

TETRAPHASE PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation